![](/img/cover-not-exists.png)
A Comparison of the Costs and Benefits of Recombinant Human Erythropoietin (Epoetin) in the Treatment of Chronic Renal Failure in 5 European Countries
Dr Brenda Leese,John Hutton,Alan MaynardVolume:
1
Language:
english
Journal:
PharmacoEconomics
DOI:
10.2165/00019053-199201050-00006
Date:
May, 1992
File:
PDF, 1021 KB
english, 1992